Clinical collaboration Strategic partnership with MD Anderson Cancer Center highlighted in 2015 suggests openness to major oncology collaborations; leverage this as a pathway to co-develop advanced targeted therapies and expand network with top-tier cancer research institutions.

Funding readiness Series B close of 7.5M in 2017 and total funding of 29M indicate active investor interest and pipeline maturity; pitch for additional capital to scale manufacturing, clinical trials, or new peptide therapies aligned with their membrane-disrupting oncology platform.

Clinical focus Emphasis on novel targeted membrane-disrupting peptides for cancer presented; target opportunities in oncology product development support, contract research, and supply of specialized peptides or related assay services for preclinical and clinical stages.

Geographic footprint Based in Louisiana with expansion to Houston, TX in 2016; potential to engage regional CROs, contract manufacturing, and logistics partners to support multi-site trials and regional regulatory affairs activities.

Executive network Past appointments of scientific advisors and board members, including connections to prominent oncology leaders; approach for advisory collaborations, KOL engagements, and strategic consulting to accelerate clinical milestones and product positioning.